Home > > > Computational Biology Market Set for Strong Growth Across Drug Discovery and Genomic Research

Computational Biology Market Set for Strong Growth Across Drug Discovery and Genomic Research

Author : savi ssd | Published On : 24 Sep 2026

The global computational biology market was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.99 billion in 2026 to USD 21.07 billion by 2034, registering a CAGR of 12.88% during 2026-2034. North America dominated the market with a 39.8% share in 2025, while Europe is expected to register the fastest CAGR of 18.91%.

  • Market Size (2025): USD 7.08 Billion

  • Market Size (2026): USD 7.99 Billion

  • CAGR (Forecast Period): 12.88%

  • Forecast Year: 2034

  • Projected Market Size (2034): USD 21.07 Billion

  • Dominant Region: North America - 39.8%

  • Fastest Growing Region: Europe - 18.91% CAGR

Market Overview

Computational biology combines biology, computer science, mathematics, and statistics to analyze complex biological data and understand genes, proteins, cells, and biological systems. Its applications span drug discovery, disease modeling, genomics, personalized medicine, bioinformatics, and clinical research.

The market is shifting toward AI-powered and multimodal computational platforms that can process increasingly complex biological datasets. Foundation models are being used to integrate multiple biological data types, predict molecular and genomic behavior, and support biological sequence design, creating broader applications across research and drug development.

Growth Drivers

AI-assisted drug discovery is strengthening the need for computational platforms that support target identification, virtual screening, molecular interaction analysis, and candidate prioritization. Pharmaceutical companies are increasingly using computational models to analyze molecular structures, predict binding affinity, and accelerate early-stage drug development.

Spatial transcriptomics and spatial proteomics are also expanding computational workloads by requiring tools that can analyze cellular location, tissue architecture, and molecular interactions. These capabilities are particularly relevant to cancer research, where spatial analysis can support biomarker discovery and characterization of tumor microenvironments.

Market Challenges

Restricted access to genomic datasets can make it difficult for computational biology companies to build and validate models using sufficiently diverse biological information. Privacy requirements, controlled-access procedures, and institution-specific data policies can also complicate commercial data partnerships and cloud-based analysis.

Regulatory uncertainty presents another challenge for companies seeking to move computational tools into clinical workflows. Unclear validation, documentation, and compliance requirements can lengthen commercialization timelines and increase the resources needed to establish clinical reliability.

Market Opportunities

Computational toxicology provides software companies with opportunities to develop predictive safety-assessment platforms for pharmaceutical, biotechnology, chemical, and agrochemical organizations. Commercial solutions such as Certara's ToxStudio demonstrate revenue avenues through software subscriptions, predictive modules, and specialized safety-analysis services.

Synthetic biology also creates opportunities for platform providers offering biological design, data management, automation, and workflow optimization tools. Companies such as Benchling demonstrate how subscription-based platforms, workflow modules, data services, and enterprise integrations can generate revenue across biotechnology research operations.

Segment Analysis

By application, the drug discovery and disease modeling segment accounted for a 34.7% share in 2025, supported by its use in target identification, biological interaction analysis, disease research, and drug development. The human body simulation software segment is expected to grow at a CAGR of 18.73% during 2026-2034, supported by virtual testing, physiological modeling, and treatment-response prediction.

By tool, the analysis software and services segment accounted for a 44.3% share in 2025 and is projected to grow at a CAGR of 18.29% during 2026-2034. Its role in genomic analysis, molecular research, disease modeling, and interpretation of large-scale datasets supports continued adoption.

By service, the in-house segment accounted for a 57.6% share in 2025, supported by greater control over sensitive research data and the ability to customize computational workflows. The contract segment is expected to grow at a CAGR of 18.54% during 2026-2034, supported by access to specialized expertise and flexible computational capabilities.

By end user, the industry and commercials segment accounted for a 61.3% share in 2025 and is projected to grow at a CAGR of 18.18% during 2026-2034. Drug discovery, genomic analysis, biomarker research, and data-driven biological research are supporting computational biology adoption across commercial organizations.

Regional Analysis

North America led the computational biology market with a 39.8% share in 2025, supported by advanced biomedical research infrastructure, strong biotechnology activity, and significant investment in computational methods and artificial intelligence. The U.S. remains the largest regional market, while Canada's genomics strategy is supporting commercialization, data access, and computational biology capabilities.

Europe is projected to register the fastest CAGR of 18.91% during 2026-2034, supported by life-science innovation programs, genomics initiatives, health-data infrastructure, and AI adoption. The U.K., Germany, and France represent important markets, with national programs supporting genomic research, precision medicine, and greater use of health data.

Asia Pacific accounted for a 22.4% share in 2025, supported by biotechnology development and government-led AI and research initiatives. China, Japan, South Korea, and India remain key markets, with investments in AI-driven scientific discovery, biotechnology, drug discovery, and national bioeconomy programs supporting regional expansion.

Competitive Landscape

The computational biology market is moderately fragmented, with life-science software companies, bioinformatics providers, genomics technology firms, computational drug-discovery companies, AI-driven biotechnology firms, and specialized research-platform providers competing across biological data analysis and drug development. Established players compete through platform breadth, validated algorithms, data resources, cloud capabilities, and enterprise integration, while emerging companies focus on AI-native models, multimodal data integration, automated workflows, and specialized biological applications.

Key companies include:

  • IBM

  • Thermo Fisher Scientific

  • Illumina

  • Agilent Technologies

  • Danaher Corporation

  • Revvity

  • DNAnexus

  • Schrödinger

  • Certara

  • Bio-Rad Laboratories

  • QIAGEN

  • Genedata

  • GeneBio

  • Compugen

  • Dassault Systèmes

  • Eurofins Scientific

Recent Developments

In June 2026, Chai Discovery signed a licensing agreement with Pfizer, enabling Pfizer to deploy Chai's AI platform and gain early access to the Chai-3 model. In May 2026, QIAGEN partnered with NVIDIA to integrate NVIDIA BioNeMo and accelerated computing with QIAGEN Digital Insights' curated bioinformatics knowledge bases.

These developments highlight the increasing integration of AI models, accelerated computing, and curated biological data into computational biology workflows, particularly across drug discovery and large-scale biological analysis.

Future Outlook

The computational biology market is expected to maintain strong growth through 2034 as pharmaceutical, biotechnology, academic, and research organizations expand their use of AI, advanced modeling, genomics, and biological data analysis. Analysis software and services, contract-based computational capabilities, and commercial applications are expected to remain important areas of expansion.

Multimodal foundation models, genome foundation models, spatial multi-omics, computational toxicology, and synthetic biology platforms are expected to shape product development. Greater integration of AI with biological datasets and high-performance computing can further expand the role of computational biology across drug discovery, disease research, and precision medicine.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/computational-biology-market

About Straits Research

Straits Research is a global market intelligence and consulting company providing market research, strategic insights, competitive analysis, and advisory services across multiple industries. The company delivers research and consulting solutions that help businesses understand market dynamics, evaluate competitive environments, identify opportunities, and support informed strategic decisions.